PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q Filing
Pacific Biosciences filed its quarterly report for the period ended March 31, 2026. The filing includes financial data such as revenue from products and services, operating expenses including research and development costs of $45 million (up from $39 million in Q1 2025), selling, general, and administrative expenses of $38 million (compared to $37 million previously). It also outlines restructuring activities under the A2025 Restructuring plan.
Tickers: $PACB